Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions


Thakur, Kiran T. Tamborska, Arina Wood, Greta K. McNeill, Emily Roh, David Akpan, Imo J. Miller, Eliza C. Bautista, Alyssa Claassen, Jan Kim, Carla Y. Guekht, Alla Pardo, Carlos A. Williams, Olajide García-Azorín, David Prasad, Kameshwar Schmutzhard, Erich Michael, Benedict D. Chou, Sherry H.-Y. Winkler, Andrea S. Solomon, Tom Elkind, Mitchell S.


Background: Vaccine induced immune mediated thrombocytopenia or VITT, is a recent and rare phenomenon of thrombosis with thrombocytopenia, frequently including cerebral venous thromboses (CVT), that has been described following vaccination with adenovirus vaccines ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2⋅S Johnson and Johnson (Janssen/J&J). The evaluation and management of suspected cases of CVT post COVID-19 vaccination are critical skills for a broad range of healthcare providers. Methods: A collaborative comprehensive review of literature was conducted among a global group of expert neurologists and hematologists. Findings: Strategies for rapid evaluation and treatment of the CVT in the context of possible VITT exist, including inflammatory marker measurements, PF4 assays, and non-heparin anticoagulation.


Journal of Neurological Sciences

Research Themes:

1. Patient Research for Public Health